TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

Model scores of the 29,894 trials active now.

Model score 30% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mdsulnprior tomonthshydroxyurea
  Phrases that lowered it: investigatorfibrosisfirst dosesubjectsprotocol
• Sponsor's past termination rate: 45.6% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 62.6% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 23.0% (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 17 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Keywords listed: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports before start: 5432 (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. NCT03427866 · started 2018 · scored riskier than 97% of active trials completed
• Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF NCT01644110 · started 2013 · scored riskier than 80% of active trials completed
• Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib NCT02226172 · started 2014 · scored riskier than 89% of active trials terminated
• Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms NCT03878199 · started 2019 · scored riskier than 83% of active trials terminated
• A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies NCT02158858 · started 2014 · scored riskier than 76% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.